Table 1 Characteristics of included studies of menarcheal age and endometrial cancer risk.
From: Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies
First author, publication year [reference], Country, Study design | Cases/subject (age), duration of follow up | Source of cases | Menarcheal age categories (exposure assessment) | RR/HR (95%CI) | Matched/Adjusted factors |
|---|---|---|---|---|---|
Yang et al.28, 2013, USA, CS | 1450/114,409 (50–69y), 9.4y | Cancer registry | <13 | 1.00 (ref) | Age, OC use, menopausal hormone therapy use, parity, BMI, age at menopause, race and smoking status |
13–14 | 0.91 (0.82–1.02) | ||||
≥15 (Self-administered questionnaire) | 0.80 (0.65–0.97) | ||||
Dossus et al.21, 2010, Europe, CS | 1017/301,601 (35–70y), 8.7y | Cancer registry | <12 | 1.00 (ref) | Age, center, BMI, physical activity, alcohol, diabetes, smoking status and education |
12 | 0.97 (0.80–1.19) | ||||
13 | 0.78 (0.63–0.95) | ||||
14 | 0.80 (0.65–0.98) | ||||
≥15 (Self-administered questionnaire) | 0.72 (0.58–0.90) | ||||
Karageorgi et al.29, 2010, USA, CS | 778/121,700 (30–55y), 28y | Medical records | ≤11 | 1.00 (ref) | Age, parity, age at first birth, age at last birth, OC duration, postmenopausal hormone use duration, BMI, smoking, diabetes, family history of endometrial cancer and age at menopause |
12 | 0.99 (0.81–1.20) | ||||
13 | 0.80 (0.66–0.98) | ||||
14 | 0.90 (0.70–1.16) | ||||
≥15 (Self-administered questionnaire) | 0.76 (0.55–1.04) | ||||
Setiawan et al.31, 2007, USA, CS | 321/46,933 (45–75y), 7.3y | Cancer registry | ≤12 | 1.00 (ref) | Race/ethnicity, BMI, age at natural menopause, parity, hormone therapy use, OC use, smoking, diabetes, hypertension, family history of endometrial cancer |
13–14 | 0.86 (0.68–1.10) | ||||
≥15 (Self-administered questionnaire) | 0.85 (0.60–1.22) | ||||
Wernli et al.9, 2006, China, CS | 206/267,400 (≥30y), 10y | Medical records | ≤13 | 1.00 (ref) | Age and parity number |
14 | 0.48 (0.28–0.82) | ||||
15 | 0.73 (0.47–1.16) | ||||
16 | 0.77 (0.49–1.20) | ||||
≥17 (Self-administered questionnaire) | 0.40 (0.25–0.63) | ||||
Hisada et al.33, 2001†, USA, NC-CS | 39/194/15,528 (N/A), 27y | Cancer registry | ≤11 | 1.00 (ref) | Age and race |
12 | 0.89 (0.18–4.30) | ||||
13 | 1.44 (0.34–6.09) | ||||
≥14 (Trained interviewer) | 0.67 (0.10–4.33) | ||||
Olson et al.30, 1999, USA, CS | 322/24,848 (55–69y), 10y | Cancer registry | ≤11 | 1.00 (ref) | Age |
11–12 | 0.7 (0.5–1.2) | ||||
12–13 | 0.6 (0.4–1.0) | ||||
>14 (Self-administered questionnaire) | 0.4 (0.2–0.8) | ||||
Kvale et al.32, 1988, Norway, CS | 420/62,079 (27–69y), 20y | Medical records | ≤12 | 1.00 (ref) | Age at start of follow-up, urban/rural place of residence and parity |
13 | N/A | ||||
14 | N/A | ||||
15 | N/A | ||||
16 | N/A | ||||
≥17 (Self-administered questionnaire) | 0.58 (0.39–0.88) |
